Journal of Surgery Concepts & Practice ›› 2022, Vol. 27 ›› Issue (04): 370-374.doi: 10.16139/j.1007-9610.2022.04.020
• Review • Previous Articles Next Articles
GUO Yang, GUO Tian′an, XU Ye()
Received:
2021-05-31
Online:
2022-07-25
Published:
2022-09-20
Contact:
XU Ye
E-mail:xu_shirley021@163.com
CLC Number:
GUO Yang, GUO Tian′an, XU Ye. Recent advance in neoadjuvant chemotherapy for rectal cancer[J]. Journal of Surgery Concepts & Practice, 2022, 27(04): 370-374.
参考文献 | 发表 年份 | 入选标准 | 总例 数 | 治疗方案 | 新辅助化 疗依从性 | 不良反应 | 病理完全 缓解率 | R0切 除率 | 局部复 发率 | 远处转 移率 | 生存率 |
---|---|---|---|---|---|---|---|---|---|---|---|
GEMCAD 0801[ | 2014, 2017 | cT3期,肿瘤位于中间1/3 | 46 | 1. XELOX+贝伐单抗(4周期,最后1周期无贝伐单抗) 2. 手术 | 不详 | 3、4级不良39.0%,2例死于新辅助化疗期 | 20.0% | 100% | 2.0% | 不详 | 1年无病生 存率75.0% |
Schrag等[ | 2014 | 距肛门边缘5~12 cm, cT3N-/ cT3N+期,cT4期者排除 | 32 | 1. mFOLFOX6(6周期)+贝伐单抗(1-4周期) 2. 肿瘤无反应/进展者进行放疗,有反应者立即进行TME | 93.8% | 2例死亡 | 25.0% | 100% | 0 | 12.5% | 4年无病生 存率84.0%, 4年总体生 存率91.6% |
Hasegawa等[ | 2017 | cT3N0M0期或T1~3 N1M0期,肿瘤远端边缘位于腹膜返折线或其下方 | 60 | 1. KRAS野生型:mFOLFOX6+贝伐单抗/西妥昔单抗(6周期),KRAS突变型:mFOLFOX6(6周期) 2. TME | 88.0% | 不详 | 16.7% | 98.3% | 不详 | 不详 | 不详 |
FACT[ | 2017 | Ⅱ/Ⅲ期;T3期或T4期 | 52 | 1. mFOLFOX6 (4周期,若结束后肿瘤无进展,则再进行 2周期) 2. TME | 96.2%(完成4周期), 84.5%(完成6周期) | 不详 | 11.9% | 92.9% | 不详 | 不详 | 不详 |
FORTUNE[ | 2019 | Ⅱ期(T3~4N0期)或Ⅲ期(T1~4 N1~2期),距肛<12 cm | 106 | 1. mFOLFOXIRI (4~6周期) 2. 任何证据表明原发肿瘤进展、新辅助化疗后直肠系膜筋膜阳性或ycT4a/b阳性的高危因素都是放疗的指征 3. TME手术 | 100% | 无死亡病人 | 20.4% | 98.8% | 不详 | 不详 | 不详 |
Toritani等[ | 2020 | 临床Ⅲ期,KRAS野生型,距肛门边缘5~12 cm | 50 | 1.mFOLFOX6 +帕尼单抗(6周期) 2. 新辅助化疗后6周内进行手术 | 96.0% | 3级不良24.0%,无4级事件或死亡病人 | 8.00% | 100% | 2.0% | 26.0% | 3年无复发 生存率 79.0%,3年 总体生存率 93.7% |
Cienfuegos等[ | 2020 | cT2~3期和(或)N+期,距肛14~15 cm内 | 27 | 1. 奥沙利铂+卡培他滨/5-FU(4~7周期) 2. 手术 | 100% | 无4级不良或死亡病人 | 14.8% | 100% | 0 | 11.0% | 5年无病生 存率84.7%, 5年总体生 存率85.0% |
[1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
doi: 10.3322/caac.21660 URL |
[2] | 王红, 曹梦迪, 刘成成, 等. 中国人群结直肠癌疾病负担:近年是否有变?[J]. 中华流行病学杂志, 2020, 41(10):1633-1642. |
[3] |
Favoriti P, Carbone G, Greco M, et al. Worldwide burden of colorectal cancer: a review[J]. Updates Surg, 2016, 68(1):7-11.
doi: 10.1007/s13304-016-0359-y URL |
[4] | 中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020年版)[J]. 中华外科杂志, 2020, 58(8):561-585. |
[5] |
Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: rectal cancer, version 6.2020[J]. J Natl Compr Canc Netw, 2020, 18(7):806-815.
doi: 10.6004/jnccn.2020.0032 URL |
[6] |
Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer[J]. Lancet, 1986, 1(8496):1479-1482.
pmid: 2425199 |
[7] |
Swedish Rectal Cancer T, Cedermark B, Dahlberg M, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer[J]. N Engl J Med, 1997, 336(14):980-987.
doi: 10.1056/NEJM199704033361402 URL |
[8] |
Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer[J]. N Engl J Med, 2001, 345(9):638-646.
doi: 10.1056/NEJMoa010580 URL |
[9] |
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. New Engl J Med, 2004, 351(17):1731-1740.
doi: 10.1056/NEJMoa040694 URL |
[10] | 王锡山. 2008至2012年美国国立综合癌症网络结直肠癌临床实践指南变化历程解读[J/CD]. 中华结直肠疾病电子杂志, 2012, 1(1):6-11. |
[11] |
Morton UKD, Seymour M, Magill L, et al. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial[J]. Lancet Oncol, 2012, 13(11):1152-1160.
doi: 10.1016/S1470-2045(12)70348-0 URL |
[12] |
Karoui M, Rullier A, Luciani A, et al. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage Ⅱ and Ⅲ colon cancers: a multicentre randomised controlled phase Ⅱ trial - the PRODIGE 22-ECKINOXE trial[J]. Bmc Cancer, 2015, 15:511.
doi: 10.1186/s12885-015-1507-3 pmid: 26156156 |
[13] |
Jakobsen A, Andersen F, Fischer A, et al. Neoadjuvant chemotherapy in locally advanced colon cancer. a phase Ⅱ trial[J]. Acta Oncol, 2015, 54(10):1747-1753.
doi: 10.3109/0284186X.2015.1037007 pmid: 25920359 |
[14] |
Liu F, Yang L, Wu Y, et al. CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase Ⅱ trial[J]. Chin J Cancer Res, 2016, 28(6):589-597.
doi: 10.21147/j.issn.1000-9604.2016.06.05 URL |
[15] |
Fernandez-Martos C, Brown G, Estevan R, et al. Pre-operative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 phase Ⅱ multicenter trial[J]. Oncologist, 2014, 19(10):1042-1043.
doi: 10.1634/theoncologist.2014-0233 pmid: 25209376 |
[16] |
Patel UB, Brown G, Machado I, et al. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial[J]. Ann Oncol, 2017, 28(2):344-353.
doi: 10.1093/annonc/mdw616 pmid: 28426108 |
[17] | Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial[J]. J Clin Oncol, 2014, 32(6):513-518. |
[18] |
Hasegawa S, Goto S, Matsumoto T, et al. A multicenter phase 2 study on the feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer[J]. Ann Surg Oncol, 2017, 24(12):3587-3595.
doi: 10.1245/s10434-017-5967-3 pmid: 28685354 |
[19] |
Koike J, Funahashi K, Yoshimatsu K, et al. Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage Ⅱ/Ⅲ rectal cancer: the FACT trial[J]. Cancer Chemoth Pharm, 2017, 79(3):519-525.
doi: 10.1007/s00280-017-3243-7 URL |
[20] | Zhang JW, Huang MJ, Cai Y, et al. Neoadjuvant chemotherapy with mFOLFOXIRI without routine use of radiotherapy for locally advanced rectal cancer[J]. Clin Colorectal Canc, 2019, 18(4):238-244. |
[21] |
Toritani K, Watanabe J, Suwa Y, et al. A prospective, single-arm, multicenter trial of neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy for locally advanced rectal cancer[J]. Int J Colorectal Dis, 2020, 35(12):2197-2204.
doi: 10.1007/s00384-020-03693-w URL |
[22] |
Cienfuegos JA, Rodriguez J, Baixauli J, et al. Neoadjuvant chemotherapy without radiotherapy for patients with locally advanced rectal cancer. Oncologic outcomes[J]. Rev Esp Enferm Dig, 2020, 112(1):16-22.
doi: 10.17235/reed.2019.6454/2019 pmid: 31729235 |
[23] |
Deng YH, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase Ⅲ trial[J]. J Clin Oncol, 2016, 34(27):3300-3307.
doi: 10.1200/JCO.2016.66.6198 URL |
[24] |
Deng YH, Chi P, Lan P, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial[J]. J Clin Oncol, 2019, 37(34):3223-3233.
doi: 10.1200/JCO.18.02309 URL |
[25] |
Sun W, Dou R, Chen J, et al. Impact of long-course neoadjuvant radiation on postoperative low anterior resection syndrome and quality of life in rectal cancer: post hoc analysis of a randomized controlled trial[J]. Ann Surg Oncol, 2019, 26(3):746-755.
doi: 10.1245/s10434-018-07096-8 URL |
[26] |
Huang M, Lin J, Yu X, et al. Erectile and urinary function in men with rectal cancer treated by neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy alone: a randomized trial report[J]. Int J Colorectal Dis, 2016, 31(7):1349-1357.
doi: 10.1007/s00384-016-2605-7 URL |
[27] |
Schrag D, Weiser M, Saltz L, et al. Challenges and solutions in the design and execution of the PROSPECT Phase Ⅱ/Ⅲ neoadjuvant rectal cancer trial (NCCTGN 1048/Alliance)[J]. Clin Trials, 2019, 16(2):165-175.
doi: 10.1177/1740774518824539 URL |
[28] |
Sclafani F, Cunningham D. Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer[J]. Future Oncol, 2014, 10(14):2243-2257.
doi: 10.2217/fon.14.127 URL |
[29] |
Marijnen CAM, van de Velde CJH, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial[J]. J Clin Oncol, 2005, 23(9):1847-1858.
pmid: 15774778 |
[30] | Massaras D, Pantiora E, Sotirova E, et al. Neoadjuvant chemoradiotherapy in rectal cancer and anorectal sphincter dysfunction: review of the literature[J]. J Buon, 2020, 25(1):35-39. |
[31] |
Sipaviciute A, Sileika E, Burneckis A, et al. Late gastrointestinal toxicity after radiotherapy for rectal cancer: a systematic review[J]. Int J Colorectal Dis, 2020, 35(6):977-983.
doi: 10.1007/s00384-020-03595-x pmid: 32296933 |
[32] |
Miwa K, Oki E, Enomoto M, et al. Randomized phase Ⅱ study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)[J]. BMC Cancer, 2021, 21(1):23.
doi: 10.1186/s12885-020-07766-5 URL |
[33] |
Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer[J]. New Engl J Med, 2006, 355(11):1114-1123.
doi: 10.1056/NEJMoa060829 URL |
[34] |
Jalil O, Claydon L, Arulampalam T. Review of neoadjuvant chemotherapy alone in locally advanced rectal cancer[J]. J Gastrointest Cancer, 2015, 46(3):219-236.
doi: 10.1007/s12029-015-9739-7 pmid: 26133151 |
[35] |
Kalisz KR, Enzerra MD, Paspulati RM. MRI evaluation of the response of rectal cancer to neoadjuvant chemoradiation therapy[J]. Radiographics, 2019, 39(2):538-556.
doi: 10.1148/rg.2019180075 pmid: 30844347 |
[36] |
Wang XH, Liu ZJ, Xu JB, et al. Baseline and early 3D-CUBE volume reconstruction of locally advanced rectal cancer to predict tumor response after neoadjuvant chemotherapy[J]. J X-Ray Sci Technol, 2020, 28(2):231-241.
doi: 10.3233/XST-190594 URL |
[37] |
Nishie A, Asayama Y, Ishigami K, et al. Amide proton transfer imaging to predict tumor response to neoadjuvant chemotherapy in locally advanced rectal cancer[J]. J Gastroen Hepatol, 2019, 34(1):140-146.
doi: 10.1111/jgh.14315 URL |
[38] |
Li ZY, Wang XD, Li M, et al. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer[J]. World J Gastroentero, 2020, 26(19):2388-2402.
doi: 10.3748/wjg.v26.i19.2388 URL |
[39] |
Zhang JW, Cai Y, Hu HB, et al. Nomogram basing pre-treatment parameters predicting early response for locally advanced rectal cancer with neoadjuvant chemotherapy alone: a subgroup efficacy analysis of FOWARC study[J]. Oncotarget, 2016, 7(4):5053-5062.
doi: 10.18632/oncotarget.6469 URL |
[40] |
He F, Yu L, Ding Y, et al. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer[J]. Cancer Sci, 2020, 111(11):4205-4217.
doi: 10.1111/cas.14636 URL |
[41] |
Oi H, Okuyama T, Miyazaki S, et al. CD133 expression predicts relapse in patients with locally advanced rectal cancer treated with neoadjuvant chemotherapy[J]. In Vivo, 2021, 35(1):437-445.
doi: 10.21873/invivo.12276 URL |
[1] | ZHAO Hui (赵晖),WEN Baiqing (文柏清),KANG Yani*(康亚妮). Gene Expression Profiling Identifies Potential Biomarkers for Colorectal Cancer Using NanoString nCounter Assay [J]. J Shanghai Jiaotong Univ Sci, 2023, 28(4): 432-. |
[2] |
WU Xiaoli, BAN Yaolin, CHEN Libin, et al.
Efficacy analysis of‘core stripping’keloid thinning surgery combined with radiotherapy [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2023, 19(1): 22-. |
[3] | SUN Qi, HUANG Wenbo, HE Bingliang, LIU Chang, XU Yuhang, ZHAO Wei. Efficacy with prognostic value of postoperative prophylactic hyperthermic intraperitoneal chemotherapy for locally advanced gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 366-370. |
[4] | YANG Yingchi, PANG Kai, ZHANG Zhongtao. Influence of neoadjuvant radiotherapy combined with immunotherapy on minimally invasive surgeries for rectal cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 186-189. |
[5] | LUO Yang, ZHONG Ming. Prevention and treatment of anastomotic leakage after laparoscopic anterior resection of low rectal cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 220-225. |
[6] | LUO Yang, YU Minhao, YE Guangyao, LIN Haiping, GONG Tingyue, LI Hao, ZHONG Ming. Efficacy of intraoperative indocyanine green fluorescence imaging evaluation for preventing anastomotic leakage after laparoscopic rectal cancer surgery [J]. Journal of Surgery Concepts & Practice, 2023, 28(03): 249-253. |
[7] | XING Ying, CHENG Shi. Neoadjuvant therapy for gallbladder cancer: current status and challenge [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 110-114. |
[8] | PAN Linfeng, XU Ximo, Batuer Aikemu, DENG Yang, ZHANG Sen, QIN Wei, SHU Duohuo, CAI Zhenghao, SONG Haiqin, YANG Xiao, ZHONG Hao, HU Yanyan, LI Jianwen, FENG Bo. Transanal total mesorectal excision in re-operation for anastomosis recurrence rectal cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 132-138. |
[9] | WANG Yuanjiang, ZOU Hao. Clinical study on comprehensive treatment of gallbladder cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(02): 171-176. |
[10] | HU Lei, XU Yalong, LIU Shaojun, HE Yiren, LIU Liu, ZHU Zhiqiang. Application of simple support bracket combined with one stitch suture in terminal ileostomy of rectal cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 77-82. |
[11] | LI Guoli, GUO Feilong. Preoperative chemotherapy through intra-arterial combined with intra-venous administration in treatment of advanced gastric cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 31-35. |
[12] | WANG Han, LU Haidi, WANG Lei, CONG Wenming, ZHENG Jianming, BAI Chenguang. Clinicopathological features of 2 cases of squamous cell carcinoma and 2 cases of adenosquamous carcinoma [J]. Journal of Diagnostics Concepts & Practice, 2023, 22(01): 44-49. |
[13] | LI Jiaxi, WANG Jinjiang, YU Liping, YUAN Ying, QIAO Guanglei, MA Lijun. Effect of RAB25 knockdown on ferroptosis of colorectal cancer cells [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(06): 710-718. |
[14] | HE Yanyan, LI Fengzhu. Primary epithelioid angiosarcoma of the bladder: clinicopathological analysis of a case and review of literature [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(06): 719-725. |
[15] | PAN Xiangou, ZHANG Li, HOU Jiazhou, DU Shisuo, ZENG Zhaochong, WANG Binliang. Study on preoperative radiotherapy in conversion therapy for patients with primary retroperitoneal soft tissue sarcoma difficult to resect or unresectable [J]. Journal of Surgery Concepts & Practice, 2022, 27(06): 530-533. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||